Publications by authors named "Poddighe P"

In B-cell malignancies, the overexpression of MYC is associated with poor prognosis, but its mechanism underlying resistance to immunochemotherapy remains less clear. In further investigations of this issue, we show here that the pharmacological inhibition of MYC in various lymphoma and multiple myeloma cell lines, as well as patient-derived primary tumor cells, enhances their susceptibility to NK cell-mediated cytotoxicity induced by conventional antibodies targeting CD20 (rituximab) and CD38 (daratumumab), as well as T cell-mediated cytotoxicity induced by the CD19-targeting bispecific T-cell engager blinatumomab. This was associated with upregulation of the target antigen only for rituximab, suggesting additional escape mechanisms.

View Article and Find Full Text PDF

Introduction: Acute promyelocytic leukemia (APL) is characterized by the gene fusion and treatment consists of all-trans retinoic acid (ATRA). Rarely, genetic APL variants have been described which are insensitive to ATRA treatment and are therefore associated with a worse prognosis. Rapid identification of the APL variant is essential to start the correct treatment.

View Article and Find Full Text PDF

Large-scale chromosomal deletions are a prevalent and defining feature of cancer. A high degree of tumor-type and subtype specific recurrencies suggest a selective oncogenic advantage. However, due to their large size it has been difficult to pinpoint the oncogenic drivers that confer this advantage.

View Article and Find Full Text PDF

In myelodysplastic syndromes (MDS) the immune system is involved in pathogenesis as well as in disease progression. Dendritic cells (DC) are key players of the immune system by serving as regulators of immune responses. Their function has been scarcely studied in MDS and most of the reported studies didn't investigate naturally occurring DC subsets.

View Article and Find Full Text PDF

Germline mutations in the Folliculin () tumor suppressor gene cause Birt-Hogg-Dubé (BHD) syndrome, a rare autosomal dominant disorder predisposing carriers to kidney tumors. is a conserved, essential gene linked to diverse cellular processes but the mechanism by which prevents kidney cancer remains unknown. Here, we show that disrupting in human renal tubular epithelial cells (RPTEC/TERT1) activates TFE3, upregulating expression of its E-box targets, including RRAGD and GPNMB, without modifying mTORC1 activity.

View Article and Find Full Text PDF
Article Synopsis
  • Complex karyotype (CK) in chronic lymphocytic leukemia (CLL) has prognostic value, and genomic arrays provide detailed detection of copy-number alterations (CNAs).
  • A study analyzed 2293 genomic arrays from 13 labs, finding significant CNAs outside typical probe regions in 34% of patients, which correlated with poorer outcomes.
  • High genomic complexity (≥5 CNAs) was identified as a strong predictor of treatment timing and overall survival, indicating that genomic arrays are effective for CLL risk stratification.
View Article and Find Full Text PDF

The bone marrow of patients with low-risk myelodysplastic syndromes (MDS) is often an inflammatory environment and associated with an active cellular immune response. An active immune response generally contributes to antitumor responses and may prevent disease progression. However, chronic immune stimulation can also induce cell stress, DNA damage and contribute to the pathogenesis of MDS.

View Article and Find Full Text PDF
Article Synopsis
  • - Daratumumab significantly lowers CD38 expression on multiple myeloma cells within hours, and this effect happens regardless of the treatment's depth or duration as seen in the GEN501 and GEN503 studies.
  • - The reduction in CD38 levels was also noted in nontumor immune cells like natural killer cells and T cells, suggesting a broader impact of the treatment beyond just tumor cells.
  • - Mechanistically, the decrease in CD38 expression is linked to a process called trogocytosis, where daratumumab-CD38 complexes are transferred to other immune cells, which may contribute to the drug's effectiveness in treating multiple myeloma.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates balanced chromosomal abnormalities (BCAs) in 273 individuals with congenital anomalies using whole-genome sequencing to achieve higher resolution than traditional karyotyping.
  • The findings revealed that 93% of karyotypes were revised, with 21% of BCAs showing complexity not detectable by standard methods, highlighting the limitations of cytogenetics.
  • The research indicated that 33.9% of BCAs caused gene disruption tied to developmental issues, and some breakpoints affected crucial genomic regions, possibly worsening conditions like 5q14.3 microdeletion syndrome due to altered gene expression.
View Article and Find Full Text PDF
Article Synopsis
  • PSMB5 mutations and increased β5 subunit expression in the proteasome are major factors in how leukemia cells develop resistance to the drug bortezomib (BTZ).
  • Research involving CCRF-CEM leukemia cells demonstrated that resistant subclones have decreased expression of stress-response genes and higher levels of the MARCKS gene, which is linked to a poor response to BTZ treatment.
  • The study indicates that MARCKS may facilitate the excretion of ubiquitinated proteins, helping resistant cells alleviate stress from proteasome inhibition, thus providing new insights into BTZ resistance mechanisms.
View Article and Find Full Text PDF

Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant disorders. IgG and IgA MGUS are precursor conditions of multiple myeloma (MM), whereas light-chain MGUS is a precursor condition of light-chain MM. Smoldering MM (SMM) is a precursor condition with higher tumor burden and higher risk of progression to symptomatic MM compared to MGUS.

View Article and Find Full Text PDF

In the past decade, patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. Standard treatment is now changing as a result of deeper understanding of underlying biologic differences of such lymphomas. One of the most powerful predictors of an adverse outcome on R-CHOP therapy is the presence of a MYC gene rearrangement (MYC+ lymphoma).

View Article and Find Full Text PDF

Mandatory for the diagnosis of myelodysplastic syndromes (MDS) is the presence of dysplasia in >10% of cells within one or more cell lineages or presence of >15% ring sideroblasts or presence of MDS-associated cytogenetic (CG) abnormalities. Discrimination between neo-plastic and non-neoplastic causes of cytopenias can be challenging when dysplastic features by cytomorphology (CM) are minimal and CG abnormalities are absent or non-discriminating from other myeloid neoplastic disorders. This study evaluated a standard diagnostic approach in 379 patients with unexplained cytopenias and highlights the additional value of flow cytometry (FC) in patients with indeterminate CM and CG.

View Article and Find Full Text PDF

Enhanced expression of ecotropic viral integration site 1 (EVI-1) occurs in ∼10% of acute myeloid leukemia (AML) patients and is associated with a very poor disease outcome. Patients with EVI-1-positive AML have poor initial responses to chemotherapy and high relapse rates, indicating an urgent need for alternative treatment strategies improving clinical outcome for these patients. Because treatment of acute promyelocytic patients with all-trans retinoic acid (ATRA) has improved the survival of these patients substantially, we investigated whether ATRA might also be effective for the subgroup of AML patients with EVI-1 overexpression.

View Article and Find Full Text PDF

Background: Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by a PML-RARA fusion due to a translocation t(15;17). Its sensitivity to treatment with all-trans retinoic acid (ATRA), which causes differentiation of the abnormal promyelocytes, combined with anthracycline based chemotherapy makes it the best curable subtype of acute myeloid leukemia. A rapid and accurate diagnosis is needed in the first place to prevent (more) bleeding problems.

View Article and Find Full Text PDF

The strongest prognostic factor in chronic B-cell lymphocytic leukemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. Determination of this mutational status is laborious and therefore not applied in routine diagnostics. A search for "surrogate markers" has been conducted over the past few years.

View Article and Find Full Text PDF

Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) is a relatively common birth defect often associated with additional congenital anomalies such as vertebral, anal, cardiovascular, renal and limb defects, the so-called VACTERL association. Yet, little is known about the causal genetic factors. Rare case reports of gastrointestinal anomalies in children with triple X syndrome prompted us to survey the incidence of structural and numerical changes of chromosome X in patients with EA/TEF.

View Article and Find Full Text PDF

The strongest prognostic factor in chronic B-cell lymphocytic leukaemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. Determination of this mutational status is laborious and therefore not applied in routine diagnostics. A search for 'surrogate markers' has been conducted over the past few years.

View Article and Find Full Text PDF

In a screening project of patients with (complex) craniosynostosis using genomic arrays, we identified two patients with craniosynostosis and microcephaly with a deletion in the 2p15p16.1 chromosomal region. This region has been associated with a new microdeletion syndrome, for which patients have various features in common, including microcephaly and intellectual disability.

View Article and Find Full Text PDF

Aim: To evaluate survival, clinical, and genetic characteristics of all patients with classic or type 1 lissencephaly born between 1972 and 1990 in the Netherlands, who at the time were enrolled in an observational study.

Method: We re-evaluated 24 patients (11 males, 13 females) for long-term follow-up and survival information.

Results: Mean length of follow-up was 14 years (SD 9 y 8 mo).

View Article and Find Full Text PDF

Background: The Netherlands are lacking reliable national empirical data in relation to the development of birth prevalence of Down syndrome. Our study aims at assessing valid national live birth prevalence rates for the period 1986-2007.

Method: On the basis of the annual child/adult ratio of Down syndrome diagnoses in five out of the eight Dutch cytogenetic centres, the national annual figures of the National Cytogenetic Network on total numbers of postnatal Down syndrome diagnoses were transformed into national figures on total numbers of postnatal Down syndrome diagnoses in newborn children only.

View Article and Find Full Text PDF

Partial monosomy 21 has been reported, but the phenotypes described are variable with location and size of the deletion. We present 2 patients with a partially overlapping microdeletion of 21q22 and a striking phenotypic resemblance. They both presented with severe psychomotor delay, behavioral problems, no speech, microcephaly, feeding problems with frequent regurgitation, idiopathic thrombocytopenia, obesity, deep set eyes, down turned corners of the mouth, dysplastic ears, and small chin.

View Article and Find Full Text PDF